Business Description
Avidity Biosciences Inc
NAICS : 541714
SIC : 2834
10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Description
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 33.69 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 13.21 | |||||
| Beneish M-Score | -3.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 132.1 | |||||
| 3-Year EBITDA Growth Rate | -79.6 | |||||
| 3-Year EPS without NRI Growth Rate | -46.7 | |||||
| 3-Year FCF Growth Rate | -71.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.65 | |||||
| 9-Day RSI | 66.4 | |||||
| 14-Day RSI | 65.2 | |||||
| 6-1 Month Momentum % | 11.52 | |||||
| 12-1 Month Momentum % | -12.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12 | |||||
| Quick Ratio | 12 | |||||
| Cash Ratio | 11.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -32.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1860.12 | |||||
| Net Margin % | -1849.49 | |||||
| ROE % | -41.25 | |||||
| ROA % | -37.2 | |||||
| ROIC % | -643.13 | |||||
| ROC (Joel Greenblatt) % | -1414.02 | |||||
| ROCE % | -40.09 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 123.27 | |||||
| PB Ratio | 2.89 | |||||
| Price-to-Tangible-Book | 2.91 | |||||
| EV-to-EBIT | -4.75 | |||||
| EV-to-Forward-EBIT | -3.9 | |||||
| EV-to-EBITDA | -4.79 | |||||
| EV-to-Forward-EBITDA | -3.92 | |||||
| EV-to-Revenue | 87.9 | |||||
| EV-to-Forward-Revenue | 182.41 | |||||
| EV-to-FCF | -6.09 | |||||
| Price-to-Net-Current-Asset-Value | 3.06 | |||||
| Price-to-Net-Cash | 3.12 | |||||
| Earnings Yield (Greenblatt) % | -21.14 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:RNA
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.988 | ||
| EPS (TTM) ($) | -3.95 | ||
| Beta | 0 | ||
| Volatility % | 48.77 | ||
| 14-Day RSI | 65.2 | ||
| 14-Day ATR ($) | 1.284363 | ||
| 20-Day SMA ($) | 18.6565 | ||
| 12-1 Month Momentum % | -12.46 | ||
| 52-Week Range ($) | 10.89 - 29.25 | ||
| Shares Outstanding (Mil) | 52.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avidity Biosciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||